Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (51-60 of 206) with videos related to

Pageof 21
Sort By:
Lancet (London, England)|May 9, 2006
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapyJustin Stebbing, Adam Sanitt, Mark Nelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphomaJustin Stebbing, Sundhiya Mandalia, Carlo Palmieri, et al.
Antiviral Therapy|March 26, 2004
Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapyAntonio Pires, Jeffrey Pido-Lopez, Graeme Moyle, et al.
AIDS (London, England)|August 4, 2011
T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsivenessJocelyn S Downey, Meriem Attaf, Graeme Moyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcomaJustin Stebbing, Adam Sanitt, Alastair Teague, et al.
AIDS (London, England)|July 2, 2005
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trialDesmond Maitland, Graeme Moyle, James Hand, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2008
The risks and incidence of K65R and L74V mutations and subsequent virologic responsesLaura Waters, Mark Nelson, Sundhiya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyRachael Jones, Justin Stebbing, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2004
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)Justin Stebbing, Mark Nelson, Chloe Orkin, et al.
AIDS (London, England)|March 22, 2006
Do the mutations M046I and I047A confer resistance to kaletra?Huw Price, Rachael Jones, Milena Stevanovic, et al.
Pageof 21

Showing results (51-60 of 206) with videos related to

Sort By:
Pageof 21
Lancet (London, England)|May 9, 2006
A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapyJustin Stebbing, Adam Sanitt, Mark Nelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphomaJustin Stebbing, Sundhiya Mandalia, Carlo Palmieri, et al.
Antiviral Therapy|March 26, 2004
Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapyAntonio Pires, Jeffrey Pido-Lopez, Graeme Moyle, et al.
AIDS (London, England)|August 4, 2011
T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsivenessJocelyn S Downey, Meriem Attaf, Graeme Moyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcomaJustin Stebbing, Adam Sanitt, Alastair Teague, et al.
AIDS (London, England)|July 2, 2005
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trialDesmond Maitland, Graeme Moyle, James Hand, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2008
The risks and incidence of K65R and L74V mutations and subsequent virologic responsesLaura Waters, Mark Nelson, Sundhiya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyRachael Jones, Justin Stebbing, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2004
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)Justin Stebbing, Mark Nelson, Chloe Orkin, et al.
AIDS (London, England)|March 22, 2006
Do the mutations M046I and I047A confer resistance to kaletra?Huw Price, Rachael Jones, Milena Stevanovic, et al.
Pageof 21